BioSpace News Archive

Aldevron the First to Rapidly Discover Human Antibodies Using Ligand’s OmniRat ® Platform and Berkeley Lights’ Beacon ® Instrument

Addario Lung Cancer Medical Institute (ALCMI) and Biodesix, Inc. today announced they will begin an observational study to prospectively evaluate the clinical utility of biomarkers, including the proteomic Primary Immune Response (PIR) test, for front-line non-small cell lung cancer (NSCLC) patients receiv

MaaT Pharma Announces Positive Data for Its Lead Microbiome Biotherapeutic MaaT013 in Intestinal Acute Graft-versus-Host-Disease at the Virtual 46 th Annual Meeting of the EBMT -- Clinical data was gathered from eleven patients with gastrointestinal (GI) aGvHD treated with MaaT013, MaaT Pharma’s full-ecosystem microbiota biotherapeutic, as part of a compassionate use program -- -- MaaT013 provided positive impact with satisfactory safety profile in al

Transaction focused on the BOXR technology including lead program BOXR1030 Company fully focused on the development of small molecule precision kinase inhibitors to treat a range of genetically driven diseases Peter Harwin appointed as Board Chair

U.S. patients with kidney failure now have access to expanded hemodialysis (HDx) therapy delivered by Theranova, a new class of dialyzer Theranova dialyzer’s unique membrane design offers a filtration profile that more closely mimics that of the natural kidney and can be used with existing hemodialysis machines 1,2 Theranova was reviewed by FDA through the De Novo process, a pathway for novel low- to moderate-risk devices

Todos Medical Ltd. (OTCQB: TOMDF) , an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for the early detection of cancer and Alzheimer’s disease, today announced that it will be presenting at the LD 500 investor conference on Thursday, September 3rd at 4:00 PM EST. Gerald Commissiong, President & CEO of Todos, will be presen

Onconova remains focused on development of its proprietary pipeline of targeted agents as it enters a new phase as a biopharmaceutical company

Immutep Limited (ASX: IMM; NASDAQ: IMMP) is pleased to announce that the Australian Research Council (ARC) has awarded Immutep and research partner Monash University a A$671,427 grant under the ARC‘s Linkage Project scheme to support their research collaboration into Lymphocyte Activation Gene-3 (LAG-3) for a further three years.

Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop oral therapies to reduce the burden of chronic injections for people with rare diseases, today announced the commercial launch and availability of MYCAPSSA® (octreotide) capsules in the United States for patients with acromegaly.

Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections, today announced the acceptance by the U.S. Food and Drug Administration (FDA) of Spero’s Investigational New Drug application (IND) for SPR720,